JP2022519704A5 - - Google Patents
Info
- Publication number
- JP2022519704A5 JP2022519704A5 JP2021546224A JP2021546224A JP2022519704A5 JP 2022519704 A5 JP2022519704 A5 JP 2022519704A5 JP 2021546224 A JP2021546224 A JP 2021546224A JP 2021546224 A JP2021546224 A JP 2021546224A JP 2022519704 A5 JP2022519704 A5 JP 2022519704A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polynucleotide
- cancer
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025003866A JP2025061188A (ja) | 2019-02-08 | 2025-01-10 | キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802847P | 2019-02-08 | 2019-02-08 | |
| US62/802,847 | 2019-02-08 | ||
| PCT/US2020/017067 WO2020163634A1 (en) | 2019-02-08 | 2020-02-06 | Chimeric cytokine receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003866A Division JP2025061188A (ja) | 2019-02-08 | 2025-01-10 | キメラサイトカイン受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519704A JP2022519704A (ja) | 2022-03-24 |
| JP2022519704A5 true JP2022519704A5 (https=) | 2023-02-09 |
Family
ID=71947958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546224A Pending JP2022519704A (ja) | 2019-02-08 | 2020-02-06 | キメラサイトカイン受容体 |
| JP2025003866A Pending JP2025061188A (ja) | 2019-02-08 | 2025-01-10 | キメラサイトカイン受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003866A Pending JP2025061188A (ja) | 2019-02-08 | 2025-01-10 | キメラサイトカイン受容体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220096549A1 (https=) |
| EP (1) | EP3920952A4 (https=) |
| JP (2) | JP2022519704A (https=) |
| KR (1) | KR20210141479A (https=) |
| CN (1) | CN113660942A (https=) |
| AU (1) | AU2020219246A1 (https=) |
| CA (1) | CA3129229A1 (https=) |
| IL (1) | IL285230A (https=) |
| WO (1) | WO2020163634A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200110576A (ko) * | 2019-03-15 | 2020-09-24 | 재단법인대구경북과학기술원 | 사이토카인 기반 면역세포 및 그의 면역 치료 용도 |
| WO2022171179A1 (zh) * | 2021-02-10 | 2022-08-18 | 苏州克睿基因生物科技有限公司 | 一种扩增增强子及其应用 |
| WO2022192346A1 (en) * | 2021-03-09 | 2022-09-15 | The Trustees Of The University Of Pennsylvania | Selective stimulation of t cells in solid tumors using oncolytic viral delivery of orthogonal il-2 |
| EP4377464A4 (en) * | 2021-07-29 | 2025-07-09 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | SYNTHETIC NUCLEIC ACID ELEMENTS TO IMPROVE CAR-T CELL EFFICACY |
| AU2022348588A1 (en) | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2025117789A1 (en) * | 2023-12-01 | 2025-06-05 | Parker Institute For Cancer Immunotherapy | Engineered immune signaling constructs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| KR102879522B1 (ko) * | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
-
2020
- 2020-02-06 WO PCT/US2020/017067 patent/WO2020163634A1/en not_active Ceased
- 2020-02-06 AU AU2020219246A patent/AU2020219246A1/en not_active Abandoned
- 2020-02-06 EP EP20751900.0A patent/EP3920952A4/en active Pending
- 2020-02-06 US US17/426,041 patent/US20220096549A1/en active Pending
- 2020-02-06 KR KR1020217028127A patent/KR20210141479A/ko not_active Ceased
- 2020-02-06 CN CN202080027249.5A patent/CN113660942A/zh active Pending
- 2020-02-06 CA CA3129229A patent/CA3129229A1/en active Pending
- 2020-02-06 JP JP2021546224A patent/JP2022519704A/ja active Pending
-
2021
- 2021-07-29 IL IL285230A patent/IL285230A/en unknown
-
2025
- 2025-01-10 JP JP2025003866A patent/JP2025061188A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519704A5 (https=) | ||
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| JP6884423B2 (ja) | 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター | |
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| Restifo et al. | Adoptive immunotherapy for cancer: harnessing the T cell response | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| US11617767B2 (en) | Armed dual CAR-T compositions and methods for cancer immunotherapy | |
| JP2024023232A5 (https=) | ||
| Morris et al. | Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer | |
| CN111892661B (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| JP2022512538A5 (https=) | ||
| Gu et al. | Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity | |
| Wang et al. | Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice | |
| JP2018531016A5 (https=) | ||
| Jacca et al. | Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer | |
| TWI817997B (zh) | 結合至階段特異性胚胎抗原4 (ssea4)之嵌合抗原受體及其用途 | |
| Bella et al. | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis | |
| JP6297641B2 (ja) | 愛玩動物の癌の補助治療としてのＨｅｒ２ＤＮＡワクチン | |
| JP7692226B2 (ja) | モノボディベースのキメラ抗原受容体及びそれを含む免疫細胞 | |
| CN116917328A (zh) | 用于癌症免疫治疗的武装双car-t组合物和方法 | |
| Ramsay et al. | Vaccine therapy and chronic lymphocytic leukaemia | |
| Ochi et al. | Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer | |
| WO2026096531A1 (en) | Antigen-specific t cell compositions and methods of making the same | |
| HK40105226A (zh) | 用於癌症免疫治疗的武装双car-t组合物和方法 |